COMPARISON OF PLATELET RICH THERAPY ALONE WITH PLATELET RICH THERAPY ALONG WITH DAILY TOPICAL 5% PROCAPIL APPLICATION FOR THE TREATMENT OF ANDROGENETIC ALOPECIA: A QUASI-EXPERIMENTAL CLINICAL TRIAL
DOI:
https://doi.org/10.55519/JAMC-02-12749Abstract
Background: Androgenetic alopecia (AGA) affects up to 50% of males and 40% of females by the age of 50. It is the result of progressive, patterned hair loss that occurs in genetically predisposed individuals having hypersensitive androgen receptors in hair follicles. Due to the variable efficacy and adverse effect profile of FDA-approved drugs, newer and alternative modalities need to be utilized. As no prior study evaluated the efficacy of Procapil in combination with platelet-rich plasma (PRP), this study aimed to fill the research gap. The objectives were to assess the effectiveness of topical Procapil 5% combined with PRP vs PRP alone in androgenetic alopecia. It was a clinical trial conducted at the Tehsil Headquarters Hospital Takhtbhai Mardan. Methods: One hundred and sixty patients with AGA were selected and divided into two groups,80 in each. Group A received 4 sessions of PRP alone, 4 weeks apart while Group B was treated with PRP in combination with topical 5%procapil solution applied twice a day. Final results are calculated at the end of 6 months using 7- 7-point patient’ satisfaction and dermatologist evaluation scoring systems. Results: The mean age in Groups A and B was 29.34±5.3 &30.22±4.8 respectively. Disease duration was comparable between both groups. At the final Assessment Greater proportion of patients in group B achieved better scores on Dermatologist evaluation and Patient satisfaction scales (p-value<0.05). Conclusion: It has been established that combining PRP with 5% Procapil yields better results in treating AGA compared to PRP used alone.References
Ahmed SA, Ayman EY, Mousa AS. Topical finasteride versus topical spironolactone in the treatment of androgenetic alopecia. Med J Cairo Univ 2020;88:1017–22.
Shankar DK, Chakravarthi M, Shilpakar R. Male androgenetic alopecia: population-based study in 1,005 subjects. Int J Trichol 2009;1(2):131.
Kaliyadan F, Nambiar A, Vijayaraghavan S. Androgenetic alopecia: an update. Indian J Dermatol Venereol Leprol 2013;79:613.
Dhurat R, Sharma A, Rudnicka L, Kroumpouzos G, Kassir M, Galadari H, et al. 5‐Alpha reductase inhibitors in androgenetic alopecia: Shifting paradigms, current concepts, comparative efficacy, and safety. Dermatol Ther 2020;33(3):e13379.
Lolli F, Pallotti F, Rossi A, Fortuna MC, Caro G, Lenzi A, et al. Androgenetic alopecia: a review. Endocrine 2017;57(1):9–17.
Skałba P, Dabkowska‐Huć A, Kazimierczak W, Samojedny A, Samojedny MP, Chełmicki Z. Content of 5‐alpha‐reductase (type 1 and type 2) mRNA in dermal papillae from the lower abdominal region in women with hirsutism. Clin Exp Dermatol 2006;31(4):564–70.
Dogan MF, Yildiz O, Arslan SO, Ulusoy KG. Potassium channels in vascular smooth muscle: a pathophysiological and pharmacological perspective. Fundam Clin Pharmacol 2019;33(5):504–23.
Chew EG, Tan JH, Bahta AW, Ho BS, Liu X, Lim TC, et al. Differential expression between human dermal papilla cells from balding and non-balding scalps reveals new candidate genes for androgenetic alopecia. J Invest Dermatol 2016;136(8):1559–67.
Traish AM. Post-finasteride syndrome: a surmountable challenge for clinicians. Fertil Steril 2020;113(1):21–50.
Schmidt AE, Refaai MA. Blood derivative therapy. Ann Blood 2022;7:1–27.
Elghblawi E. Platelet‐rich plasma, the ultimate secret for youthful skin elixir and hair growth triggering. J Cosmet Dermatol 2018;17(3):423–30.
Feigin K, Shope B. Use of platelet-rich plasma and platelet-rich fibrin in dentistry and oral surgery: introduction and review of the literature. J Vet Dent 2019;36(2):109–23.
Hajipour H, Farzadi L, Latifi Z, Keyhanvar N, Navali N, Fattahi A, et al. An update on platelet-rich plasma (PRP) therapy in endometrium and ovary related infertilities: clinical and molecular aspects. Syst Biol Reprod Med 2021;67(3):177–88.
Li J, Yang Z, Li Z, Gu L, Wang Y, Sung C. Exogenous IGF-1 promotes hair growth by stimulating cell proliferation and down regulating TGF-β1 in C57BL/6 mice in vivo. Growth Horm IGF Res 2014;24(2-3):89–94.
Tyagi BP, Rout M. Platelet rich plasma (PRP): a revolutionary treatment of sensorineural hearing loss. Acta Sci Otolaryngol 2019;1(4):1–4.
Paichitrojjana A, Paichitrojjana A. Platelet rich plasma and its use in hair regrowth: a review. Drug Des Devel Ther 2022;16:635–45.
Yepuri V, Venkataram M. Platelet-rich plasma with microneedling in androgenetic alopecia: study of efficacy of the treatment and the number of sessions required. J Cutan Aesthet Surg 2021;14(2):184–90.
Cavallo C, Roffi A, Grigolo B, Mariani E, Pratelli L, Merli G, et al. Platelet-rich plasma: the choice of activation method affects the release of bioactive molecules. Biomed Res Int 2016;2016:6591717.
Karaca N, Akpolat ND. A comparative study between topical 5% minoxidil and topical “Redensyl, Capixyl, and Procapil” combination in men with androgenetic alopecia. J Cosmetol Trichol 2019;2019:150370987.
Kohli M, Choudhury B. Cosmeceuticals in Hair Care. In: Essentials for Aesthetic Dermatology in Ethnic Skin: Practice and Procedure: 2023.
Sehgal VN, Kak R, Aggarwal A, Srivastava G, Rajput P. Male pattern androgenetic alopecia in an Indian context: a perspective study. J Eur Acad Dermatol Venereol 2007;21(4):473–9.
Jang WS, Son IP, Yeo IK, Park KY, Li K, Kim BJ, et al. The annual changes of clinical manifestation of androgenetic alopecia clinic in korean males and females: a outpatient-based study. Ann Dermatol 2013;25(2):181–8.
Manickam N, Mathapati P, Somasundaram K, Gopalan K, Ganga Vellaisamy S. Efficacy of Platelet-Rich Plasma in Males with Androgenetic Alopecia. Cureus 2023;15(3):e36531.
Aftab K, Iftikhar N, Hussain M, Obaid S, Zainab Z, Mumtaz M. Usefulness of Platelet Rich Plasma in Androgenetic Alopecia. Pak Armed Forces Med J 2022;72(1):112–4.
Verma K, Tegta GR, Verma G, Gupta M, Negi A, Sharma R. A study to compare the efficacy of platelet-rich plasma and minoxidil therapy for the treatment of androgenetic alopecia. Int J Trichology 2019;11(2):68–79.
Sharma HK, Chauhan PS, Mehta KS, Mahajan VK, Chandel M, Verma Y, et al. A study to compare the efficacy and safety of platelet rich plasma and topical minoxidil fortified with finasteride in the treatment of androgenic alopecia in male patients. Indian J Clin Exp Dermatol 2022;8(2):91–6.
Elena EP, Irina OS. Platelet-rich plasma and minoxidil leads to better clinical results than monotherapy with these methods in men with androgenetic alopecia. Int J Trichology 2022;12(1):1–7.
Pavithra TR, Rajashekar TS, Prasanna H. A Comparative Study of Topical Procapil With Platelet-Rich Plasma Therapy Versus Topical Redensyl, Saw Palmetto, and Biotin With Platelet-Rich Plasma Therapy in the Treatment of Androgenetic Alopecia. Cureus 2023;15(5):e38696.
Additional Files
Published
Issue
Section
License
Copyright (c) 2024 Hina Khoso, Muhammad Fahim
This work is licensed under a Creative Commons Attribution-NoDerivatives 4.0 International License.
Journal of Ayub Medical College, Abbottabad is an OPEN ACCESS JOURNAL which means that all content is FREELY available without charge to all users whether registered with the journal or not. The work published by J Ayub Med Coll Abbottabad is licensed and distributed under the creative commons License CC BY ND Attribution-NoDerivs. Material printed in this journal is OPEN to access, and are FREE for use in academic and research work with proper citation. J Ayub Med Coll Abbottabad accepts only original material for publication with the understanding that except for abstracts, no part of the data has been published or will be submitted for publication elsewhere before appearing in J Ayub Med Coll Abbottabad. The Editorial Board of J Ayub Med Coll Abbottabad makes every effort to ensure the accuracy and authenticity of material printed in J Ayub Med Coll Abbottabad. However, conclusions and statements expressed are views of the authors and do not reflect the opinion/policy of J Ayub Med Coll Abbottabad or the Editorial Board.
USERS are allowed to read, download, copy, distribute, print, search, or link to the full texts of the articles, or use them for any other lawful purpose, without asking prior permission from the publisher or the author. This is in accordance with the BOAI definition of open access.
AUTHORS retain the rights of free downloading/unlimited e-print of full text and sharing/disseminating the article without any restriction, by any means including twitter, scholarly collaboration networks such as ResearchGate, Academia.eu, and social media sites such as Twitter, LinkedIn, Google Scholar and any other professional or academic networking site.
